BioCentury
ARTICLE | Clinical News

CTI's pacritinib meets Phase III endpoint

March 10, 2015 2:17 AM UTC

CTI BioPharma Corp. (NASDAQ:CTIC) gained $0.16 to $2.81 after reporting pacritinib met the primary endpoint of the Phase III PERSIST-1 trial to treat patients with primary or secondary myelofibrosis (MF).

A statistically significant proportion of patients receiving pacritinib achieved a 35% or greater reduction in spleen volume from baseline to week 24 compared to those receiving the best available therapy, excluding Janus kinase-2 inhibitors (p=0.0003). On a conference call, president and CEO Jim Bianco said preliminary analyses at 36 weeks and 48 weeks suggest continued improvement, consistent with results from Phase II testing, although the company has yet to report 48-week data. ...